UBS Group Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price

Nuvation Bio (NYSE:NUVB) had its price target dropped by stock analysts at UBS Group from $10.00 to $7.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group’s price objective suggests a potential upside of 47.68% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on NUVB. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a report on Thursday, January 22nd. HC Wainwright dropped their target price on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating for the company in a report on Monday, January 12th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday, February 10th. Royal Bank Of Canada lifted their target price on Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nuvation Bio has a consensus rating of “Moderate Buy” and an average price target of $11.44.

Nuvation Bio Trading Up 8.7%

Nuvation Bio stock opened at $4.74 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.95 and a quick ratio of 8.39. The firm has a 50-day moving average of $6.45 and a 200-day moving average of $5.53. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -7.90 and a beta of 1.50. Nuvation Bio has a one year low of $1.54 and a one year high of $9.75.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). The company had revenue of $41.87 million for the quarter, compared to analysts’ expectations of $36.82 million. Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%. On average, equities analysts expect that Nuvation Bio will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nuvation Bio

A number of hedge funds have recently bought and sold shares of NUVB. HighTower Advisors LLC boosted its stake in Nuvation Bio by 9.8% in the 4th quarter. HighTower Advisors LLC now owns 22,457 shares of the company’s stock worth $201,000 after purchasing an additional 2,007 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after acquiring an additional 2,597 shares during the last quarter. LCM Capital Management Inc grew its stake in shares of Nuvation Bio by 29.2% during the third quarter. LCM Capital Management Inc now owns 15,500 shares of the company’s stock valued at $57,000 after buying an additional 3,500 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Nuvation Bio by 17.7% during the 4th quarter. Russell Investments Group Ltd. now owns 24,456 shares of the company’s stock valued at $219,000 after buying an additional 3,681 shares in the last quarter. Finally, Meridian Wealth Management LLC grew its position in shares of Nuvation Bio by 3.8% during the 4th quarter. Meridian Wealth Management LLC now owns 113,565 shares of the company’s stock worth $1,018,000 after buying an additional 4,200 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Key Headlines Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Nuvation says it is transitioning to a commercial-stage company with progress for Iptrozi (IBTROZI) and safusidenib, signaling revenue-led growth and a commercialization focus that investors prize. Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress
• Positive Sentiment: Q4/2025 results showed revenue above consensus ($41.9M vs. $36.8M) and management highlighted strong market acceptance of its marketed oncology product(s) and an expanding partner footprint — supportive for near-term commercial revenue. Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst support: Royal Bank of Canada raised its price target to $13 and kept an outperform rating, which can boost investor sentiment about upside to commercialization prospects. Benzinga: RBC raises PT to $13
• Positive Sentiment: Management outlined a first‑line growth strategy for IBTROZI with a long median duration of response (~50 months) and expanding global partnerships, reinforcing the product’s commercial potential. Nuvation Bio outlines first-line IBTROZI growth strategy
• Negative Sentiment: A law firm (Johnson Fistel) announced an investigation into potential securities-law claims involving NUVB and its executives, raising governance/legal risk that can pressure the stock if it develops. Johnson Fistel investigation notice
• Negative Sentiment: TipRanks flagged new commercialization and partner-execution risks for taletrectinib, underscoring execution challenges that could limit upside if partnerships or launches underperform. Taletrectinib commercialization risks
• Negative Sentiment: UBS cut its price target from $10 to $7 and placed a neutral rating, a downgrade that may weigh on sentiment even though other analysts remain more bullish. Benzinga: UBS lowers PT to $7

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.